High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission
Ignazio Majolino, Marco Ladetto, Anna Locasciulli, Daniela Drandi, Fabio Benedetti, Andrea Gallamini, Teodoro Chisesi, Angelo De Blasio, Mario Boccadoro, Corrado Tarella
Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review
Fingerprint
Entra nei temi di ricerca di 'High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission'. Insieme formano una fingerprint unica.